Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | AGXT | P21549 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185216 | 0.86 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1IDO1TDP1 | |
| SCHEMBL23001580 | 0.82 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL419807 | 0.82 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL6700653 | 0.81 | TDP1 (0.59) | ALDH1A1MAPK1L3MBTL1IDO1TDP1 | |
| SCHEMBL15708326 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL3439041 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL6951942 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL7634923 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Hydrochloric Acid SCHEMBL6700651 | 0.80 | TDP1 (0.58) | ALDH1A1MAPK1L3MBTL1IDO1TDP1 | |
| SCHEMBL42974 | 0.80 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190336462-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-11-07 | — | — | US | disclosed |
| US-10335382-B2 | Use of hydrogen sulfide synthesis inhibitors for cancer therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-02 | — | — | US | disclosed |
| US-20160095831-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160095831-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-07 | — | — | US | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
| US-5252731-A | Antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| US-5110921-A | Bactericides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| US-4960889-A | CEPHALOSPORIN INTERMEDIATES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-02 | — | — | US | disclosed |
| US-4731443-A | 7-acylamino-3-vinylcephalosporanic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
| US-4487927-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4423213-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336462-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | CBS, CTH, HCCS | ALDH1A1 919/4885MAPK1 2967/4885L3MBTL1 2218/4885 |
| US-20160095831-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | CBS, CTH, HCCS | ALDH1A1 919/4885MAPK1 2967/4885L3MBTL1 2218/4885 |
| US-10335382-B2 | Use of hydrogen sulfide synthesis inhibitors for cancer therapy | CBS, CTH, HCCS | ALDH1A1 919/4885MAPK1 2967/4885L3MBTL1 2218/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | ALDH1A1 583/4885MAPK1 3104/4885L3MBTL1 2554/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | ALDH1A1 583/4885MAPK1 3104/4885L3MBTL1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.